Moreover, when small-cell lung cancer (SCLC) cells acquire chemoresistance, HER2 is frequently upregulated and acts as a biomarker of poor prognosis in advanced cases [206,207,208]. This evidence concerns the gene ERBB2 and small cell lung carcinoma.